Common Sense Overview

  • Founded
  • 1999

Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $500K

Common Sense General Information

Description

Developer of non-invasive diagnostic products for women designed to classify common abnormal vaginal discharges. The company's products uses a testing technology that can be embedded into products, including panty liners, that assess for vaginal bacterial infections, as well as for amniotic-fluid leaks during the final phase of pregnancy, enabling women to track their health via color coding and act accordingly.

Contact Information

Website
www.peptonicmi.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Parent Company
PEPTONIC Medical
Primary Office
  • 7 Ha'Eshel, Zone 2 Caesarea Industrial Park
  • Caesarea 38900
  • Israel
+972 00-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Common Sense Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 06-Oct-2021 $500K 000 00000 Completed Generating Revenue
3. Out of Business 01-Jan-2018 Cancelled Generating Revenue
2. Secondary Transaction - Private 01-Feb-2014 $5M Completed Generating Revenue
1. Early Stage VC $5M $5M Completed Generating Revenue
To view Common Sense’s complete valuation and funding history, request access »

Common Sense Patents

  • 61

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Common Sense Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019204327-A1 Diagnostic composition for identifying amniotic fluid Active 01-Jul-2014 000000000
AU-2019204327-B2 Diagnostic composition for identifying amniotic fluid Active 01-Jul-2014 000000000
AU-2015283587-A1 Diagnostic composition for identifying amniotic fluid Active 01-Jul-2014 000000000
AU-2015283587-B2 Diagnostic composition for identifying amniotic fluid Active 01-Jul-2014 000000000
CA-2953886-C Diagnostic composition for identifying amniotic fluid Active 01-Jul-2014 A61L15/56
To view Common Sense’s complete patent history, request access »

Common Sense Executive Team (8)

Name Title Board Seat Contact Info
Avishay Levanovsky Chief Executive Officer & Board Member
Amir Karp Chief Operating Officer
Hadar Shoham Ph.D Director, Clinical Studies & Biological Research
You’re viewing 3 of 8 executive team members. Get the full list »

Common Sense Board Members (9)

Name Representing Role Since
Avishay Levanovsky Common Sense Chief Executive Officer & Board Member 000 0000
Craig Sanders Self Chairman 000 0000
Douglas Sanders Self Board Member 000 0000
Ngai Lau Self Board Member 000 0000
Phyllis Sanders Common Sense Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Common Sense Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioMedical Innovations Management Venture Capital Minority 000 0000 000000 0
Fishman Group PE/Buyout Minority 000 0000 000000 0
Foriland Investments Venture Capital Minority 000 0000 000000 0
Israel Technology Partners Venture Capital Minority 000 0000 000000 0
Latartech Holdings Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial